Fatal cytokine release syndrome by an aberrant FLIP/STAT3 axis 1

2

Chiara Musiu^{1†}, Simone Caligola^{1†}, Alessandra Fiore^{1,2†}, Alessia Lamolinara³, Cristina 3 Frusteri¹, Francesco Domenico Del Pizzo³, Francesco De Sanctis¹, Stefania Canè¹, Annalisa 4 Adamo¹, Francesca Hofer¹, Roza Maria Barouni¹, Andrea Grilli⁴, Serena Zilio⁵, Paolo 5 Serafini⁵, Evelina Tacconelli⁶, Katia Donadello⁷, Leonardo Gottin⁷, Enrico Polati⁷, Domenico 6 Girelli⁸, Ildo Polidoro⁹, Piera Amelia Iezzi⁹, Domenico Angelucci¹⁰, Andrea Capece¹⁰, Ying 7 Chen^{11,12}, Zheng-Li Shi¹¹, Peter J. Murray², Marco Chilosi¹³, Ido Amit¹⁴, Silvio Bicciato⁴, 8 Manuela Iezzi³, Vincenzo Bronte^{1+*} and Stefano Ugel^{1+*} 9

- 10
- ¹Immunology Section, Department of Medicine, University and Hospital Trust of Verona, 37134 11
- 12 Verona, Italy.
- 13 ²Max Planck Institute of Biochemistry, Martinsried 82152, Germany
- 14 ³CAST- Center for Advanced Studies and Technology, Department of Neurosciences Imaging and
- Clinical Sciences, University of G. D'Annunzio of Chieti-Pescara, 66100 Chieti, Italy 15
- ⁴Department of Life Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy. 16
- ⁵Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, 17 18 Miami, FL, United States
- 19 ⁶Division of Infectious Diseases, Department of Diagnostics and Public Health, University and Hospital Trust of Verona, 37134 Verona, Italy. 20
- ⁷Intensive Care Unit, Department of Surgery, Dentistry, Maternity and Infant, University and 21 Hospital Trust of Verona, 37134 Verona, Italy. 22
- ⁸Division of Internal Medicine, Department of Medicine, University and Hospital Trust of Verona, 23 24 37134 Verona, Italy.
- ⁹Complex Operational Unit of Forensic Medicine, Local Health Authority of Pescara, 65124 Pescara, 25 26 Italy.
- ¹⁰Pathological Anatomy Unit, Local Health Authority of Lanciano-Vasto-Chieti, 66054, Vasto, Italy. 27
- ¹¹CAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety 28 Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, People's Republic of China. 29
- ¹²University of Chinese Academy of sciences, Beijing, People's Republic of China. 30
- ¹³Department of Pathology, Pederzoli Hospital, 37019 Peschiera del Garda, Italy 31
- 32 ¹⁴Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
- [†]shared first authors 33
- 34 ^{*}shared last authors
- *correspondence: vincenzo.bronte@univr.it and stefano.ugel@univr.it 35
- 36
- 37
- 38

40 Abstract

Inflammatory responses rapidly detect pathogen invasion and mount a regulated reaction. However, dysregulated anti-pathogen immune responses can provoke life-threatening inflammatory pathologies collectively known as cytokine release syndrome (CRS), exemplified by key clinical phenotypes unearthed during the SARS-Cov-2 pandemic. The underlying pathophysiology of CRS remains elusive. We found that FLIP, a protein that controls caspase-8 death pathways, was highly expressed in myeloid cells of COVID-19 lungs. FLIP controlled CRS by fueling a STAT3-dependent inflammatory program. Indeed, constitutive expression of a viral FLIP homologue in myeloid cells triggered a STAT3-linked, progressive and fatal inflammatory syndrome in mice, characterized by elevated cytokine output, lymphopenia, lung injury and multiple organ dysfunctions that mimicked human CRS. As STAT3-targeting approaches relieved inflammation, immune disorders, and organ failures in these mice, targeted intervention towards this pathway could suppress the lethal CRS inflammatory state.

59 One sentence summary

61 FLIP-expressing myeloid cells are key drivers of CRS through aberrant overexpression of 62 STAT3 pathway. STAT3-targeting is effective in mitigating CRS like severe COVID-19.

81 Introduction

82

Host responses to pathogens are ordered, time-dependent and tissue-compartmentalized, 83 coordinated by the release of soluble factors, such as growth factors and inflammatory 84 cytokines, which engage, activate and regulate innate immune cells(1). Since the 85 magnitude of the immune response is generally consistent with the pathogen load and 86 restrained to the invasion area, cytokines with short half-life have a limited action at sites 87 of inflammation and favor the local activation of immune cells. However, persistent 88 infections or an uncontrolled microbial burden can prompt higher output of cytokines, 89 which fuel emergency hematopoiesis to mobilize an increased number of leukocytes from 90 91 the bone marrow and thus counterbalance the myeloid cell depletion in periphery(2). Under these circumstances, the increase in cytokines beyond the normal thresholds can 92 cause a catastrophic cytokine storm known as cytokine release syndrome (CRS), which 93 eventually leads to multiple organ failures(3). This systemic pathology is not only 94 95 associated with disseminated bacterial or viral infections (4, 5) but also induced by cancer immunotherapy, i.e. chimeric antigen receptor (CAR) T cells infusion or antibody-based 96 therapy(6-10), stem cell transplantation settings(11), as well as linked to either 97 autoimmune or genetic disorders (12, 13). Patients with CRS frequently display respiratory 98 symptoms including tachypnea that progress to acute respiratory distress syndrome 99 (ARDS)(14), severe kidney injury, hepatobiliary damage, cardiomyopathy and neurological 100 dysfunctions(3). 101

102

Accumulating evidence suggests a close relationship between CRS and the pandemic of 103 coronavirus disease 2019 (COVID-19) induced by severe acute respiratory syndrome 104 coronavirus 2 (SARS-CoV-2)(15-17). Indeed, pathophysiological features of severe COVID-105 19 patients were often associated with pulmonary involvement that can require invasive 106 mechanical ventilation in intensive care units (ICU)(18-21). After virus entry, SARS-CoV-2 107 induces endothelial cell damage, complement activation, thrombin production and 108 fibrinolysis inhibition that result in pulmonary intravascular coagulation, vascular 109 microthrombi formation and, ultimately, severe vasculopathy, acute myocardial infarction 110 and stroke(22, 23). Moreover, several studies have reported SARS-CoV-2 organotropism in 111 myocardial, renal, neural and gastrointestinal tissues, confirming COVID-19 as a complex 112 pathology with multiple manifestations(24). These multi-organ damages may be 113 associated to an either direct viral toxicity or virus-dependent dysregulation of the immune 114 system(25-30). Thus, activation of innate immune system can be considered the main 115 hallmark of SARS-CoV-2-associated CRS, as recently reviewed(31). Indeed, myeloid cells 116 are actively involved in the establishment of acute lymphopenia, microvascular 117 dysfunctions and organ failure, all key features of COVID-19-associated CRS(27, 32-34). 118 To date, however, a molecular understanding of the SARS-CoV-2-dependent myeloid cell 119 reprogramming remains elusive. 120

We previously identified the anti-apoptotic cellular and viral FLICE (FADD-like IL-1β-122 converting enzyme)-like inhibitory proteins (hereafter c-FLIP and v-FLIP respectively) as a 123 factor that "reprogrammed" monocytes(35). FLIP isoforms are conventionally described to 124 control cell survival and proliferation as caspase-8 inhibitor and/or NF-κB activator(36-40). 125 However, FLIPs regulate different biological processes based on their protein structure 126 (e.g. the presence of death effector domains in tandem)(41) or cellular localization (e.g. 127 trafficking between the nucleus and cytoplasm)(42, 43). The up-regulation of FLIP 128 monocytes promoted the acquisition of unconventional 129 proteins in phenotype characterized by the concurrent expression of immunosuppressive (e.g. programmed 130 death-ligand 1 (PD-L1), IL-10) and pro-inflammatory (e.g. interleukin (IL)-1 β , IL-6, tumor 131 necrosis factor (TNF)- α) features, which partially depend on the nuclear translocation of 132 the complex FLIP/nuclear factor kappa B p50 (NF- κ B p50) protein(35). In transgenic 133 ROSA26.vFLIP;LyzM-CRE mice, where Kaposi's sarcoma virus vFLIP expression is enforced 134 in myeloid cells, a severe and lethal inflammatory pathology developed, resembling Kaposi 135 sarcoma-associated herpesvirus inflammatory cytokine syndrome(35). 136

137

We suspected FLIP- and pSTAT3-expressing myeloid cells were linked to COVID-19-138 associated CRS since their accumulation was shared by both human (h)ACE2-expressing 139 transgenic mice and patients infected by SARS-CoV-2. Moreover, monocytes isolated from 140 COVID-19 patients showed high myeloid expression of c-FLIP and pSTAT3 that correlated 141 with their immunosuppressive properties. We established that vFLIP transgenic mice 142 mirror both the immune dysfunctions and the bronchoalveolar immune landscape of 143 patients affected by severe COVID-19. We used this unique model to assess both systemic 144 and myeloid-targeted STAT3 interference approaches to resolve uncontrolled inflammation 145 and acute disease manifestations. 146

147

148 **Results**

149

SARS-CoV-2 infection induced c-FLIP overexpression in both COVID-19 patients and virusinfected, HFH4-hACE2 transgenic mice.

Viruses have evolved a myriad of ways to escape host apoptotic process and thereby 152 preserve infected cells from early death, which eliminates the replicative niche(44). 153 Several viruses including hepatitis C virus(45), hepatitis B virus(46), human T cell leukemia 154 virus-1(47), human immunodeficiency virus 1(48), Epstein Barr Virus(49) and influenza A 155 virus(50) induce the anti-apoptotic protein c-FLIP, which blocks caspase-mediated cell 156 death(40). Poxviruses and herpesviruses encode proteins with high homology to c-FLIP, 157 such as the Kaposi's herpesvirus K13/vFLIP and the herpesvirus saimiri orf71, which 158 harbor DED domains responsible for blocking procaspase cleavage, preventing apoptosis 159 and favoring viral latency(36). Thus, FLIP expression is linked to viral replication by 160 suppressing host cell death. 161

To examine c-FLIP alterations in COVID-19, we analyzed lung autopsy samples from 163 patients infected by SARS-CoV-2 (COVID-19; n=23) or affected by bacterial pneumonia 164 (BP; n = 4) or other diseases (NRD; n = 4) (Supplementary information, Table S1a). In the 165 latter group, the respiratory tract was not altered by severe inflammation and showed a 166 tissue structure almost devoid of pathological aspects (Fig. 1a, first line). By contrast, the 167 histopathological features of the lungs from COVID-19 patients were showed 168 heterogeneous inflammation and tissue damage (Supplementary information, Fig. 169 S1a)(22, 51). When we evaluated the number of CD68⁺ myeloid cells, which encompass 170 alveolar macrophages, monocytes/interstitial macrophages and histiocytes(52, 53), for the 171 expression of FLIP, COVID-19 samples displayed a variable number of FLIP-expressing 172 CD68⁺ cells (Fig. 1a, second line) suggesting an accumulation of FLIP⁺ myeloid cells 173 during COVID-19 progression. Previously, we found enforced FLIP expression 174 reprogramming myeloid cells into immune regulatory elements through the aberrant 175 activation of several molecular pathways, including STAT3-dependent signaling(35). Since 176 STAT3 hyperactivation was advanced as the orchestrator of most commonly COVID-19-177 associated features, such as rapid coagulopathy, thrombosis, tissue fibrosis, production of 178 inflammatory cytokines and chemokines, as well as T cell lymphopenia, we next evaluated 179 the expression of pSTAT3 in the selected pathological lung fields. We detected a weak 180 pSTAT3 expression in NRD samples, while a limited pSTAT3 pattern was restricted to 181 stromal cells in bacterial pneumonia sections. However, consistent and diffuse expression 182 of pSTAT3 was shared in COVID-19 samples by numerous cell types; among them, several 183 CD68⁺FLIP⁺ alveolar macrophages (Fig. 1a, third and fourth lines), histiocytic cells (Fig. 184 1a, fifth and sixth lines) and monocytes/interstitial macrophages (Supplementary 185 information, Fig. S1b). Interestingly, CD68+FLIP+pSTAT3+ cells were present in 56.5% 186 (13/23) of analyzed cases and their presence significantly correlated with a shorter time to 187 fatal evolution, expressed as number of hospitalization days (i.e. absence of 188 CD68+FLIP+pSTAT3+ cells (n=10) 25 \pm 14.4 days vs. presence of CD68+FLIP+pSTAT3+ 189 cells (n=13) 18 ± 9.3 days; p=0.0223) (Supplementary information, Table S1b). 190

191

We assessed c-FLIP and pSTAT3 expression in fresh circulating monocytes isolated from 192 SARS-CoV-2 infected individuals (Supplementary information, Table S1c). 193 Immunofluorescence analysis revealed an increased expression of c-FLIP in monocytes 194 isolated from COVID-19 patients compared to heathy donors (HDs) (Fig. 1b), together 195 with a linear correlation between c-FLIP-expression in monocytes and their 196 immunosuppressive properties (Fig. 1c). PD-L1 was enhanced in c-FLIP-expressing CD14+ 197 cells (Supplementary information, Fig. S1c), in agreement with our previous findings in 198 pancreatic ductal adenocarcinoma (PDAC) patients(35), hinting to common mechanisms of 199 innate immunity modulation in COVID-19 and cancer. 200

201

We next sought to determine whether c-FLIP-expressing monocytes exhibited concomitant activation of STAT3. We identified a significant direct correlation between pSTAT3 and c-

FLIP expression in circulating CD14⁺ cells isolated from COVID-19 patients (Fig. 1d), 204 hinting to the aberrant activation of FLIP/STAT3 axis in myeloid cells not only at 205 pulmonary site but also in periphery. The STAT3 pathway in myeloid cells is relevant for 206 acquiring immunosuppressive functions (54-56) and for driving production of cytokines 207 during immune disorders (57), two conditions jointly cooperating to establish a severe 208 lymphopenia, one the signs of clinical severity in COVID-19 patients. Monocytes isolated 209 from COVID-19 patients secreted a greater amount of cytokines, on a per-cell basis, which 210 correlated with the pSTAT3 expression (Fig. 1e and Supplementary information, Fig. S1e), 211 consistent with published data about the monocyte contribution to the cytokine storm (58, 212 213 *59*).

214

To establish a direct link between FLIP and pSTAT3 dysregulation following SARS-Cov-2 215 infection, we analyzed the lung of mice transgenic for hACE2 (HFH4-hACE2 mice) that 216 were intranasally infected with either SARS-CoV-2 or mock virus, as previously 217 described (60). Examination of lung tissues 7 days after virus challenge demonstrated that 218 SARS-CoV-2 infection induced severe pneumonia characterized by increased CD11b⁺ 219 myeloid cell accumulation in perivascular and alveolar locations (Fig. 1f). Of note, lung-220 infiltrating myeloid cells in SARS-CoV-2-infected mice expressed higher p-STAT3 levels 221 than the control group (Fig. 1f). Moreover, we found an increased expression of p-STAT3 222 in c-FLIP-expressing cells, which morphologically resemble myeloid cells, in the lung of 223 SARS-CoV-2-infected mice (Fig. 1f). 224

225

226 Collectively, these data establish that myeloid subsets are converted into FLIP- and 227 pSTAT3-expressing elements characterized by pro-inflammatory and immunosuppressive 228 features in COVID-19.

229

vFLIP overexpression in myeloid cell lineage induced pulmonary and systemic pathological features of CRS, including the fatal outcome.

Since transgenic mice expressing v-FLIP in myeloid cells die prematurely within four weeks 232 of life due to systemic immune disorders(35), we engrafted sub-lethally ablated, 233 immunocompetent mouse recipients with bone marrow (BM) isolated from either 234 ROSA26.vFLIP;LyzM-CRE (CD45.2) or wild type mice (CD45.1) mixed together at different 235 ratios. All engrafted mice developed weight loss (Supplementary information, Fig. S2a-b), 236 systemic lymphopenia and extensive accumulation of myeloid cells in the spleen, where a 237 subversion of splenic architecture was marked (Supplementary information, Fig. S2c), as 238 well as in several organs leading to the development of multi-organ injuries and areas of 239 fibrosis (Supplementary information, Fig. S2d), including the lung. For subsequent 240 analyses in this study we employed BM chimeras (hereafter defined vFLIP mice), 241 generated by transplantation of a 1:1 ratio of vFLIP⁺ and WT BM cells. 242

Since lung inflammation is the principal cause of life-threatening respiratory syndrome in 244 CRS, including severe forms of COVID-19(20), we assessed the lung histopathology in 245 vFLIP mice. Lungs of vFLIP mice showed diffuse interstitial myeloid infiltrate and alveolar 246 damage, characterized by areas of fibrosis, lung consolidation, multinucleated cell clusters 247 and tissue regions with peribronchial and perivascular infiltrate with associated 248 intravascular thrombi. Severe cases also showed infarctions and extensive fibrosis (Fig. 2a-249 b, Supplementary information, Fig. S3a). Consistent with COVID-19 CRS, we detected 250 pSTAT3 in myeloid cells localized in vFLIP lung tissues compared to normal mice (Fig. 2c). 251 Considering the role of an aberrant immune response in the pathogenesis of COVID-19 by 252 promoting alveolar inflammation and hyper-coagulation state in lung vessels (26, 61), we 253 evaluated the presence of the endothelial dysfunction marker p-selectin in the pulmonary 254 environment of vFLIP mice. P-selectin is normally stored in Weibel-Palade bodies of 255 endothelial cells. After tissue injury, it is exposed in the vascular lumen where it mediates 256 the adhesion and activation of platelets and leukocytes(62). In vFLIP mice, p-selectin was 257 strongly expressed on the luminal surface of inflamed vessels of large and small caliber, 258 whereas it was not detectable in the lungs of WT mice (Fig. 2d). 259

260

Among effector mechanisms of neutrophils during inflammatory processes, neutrophil-261 derived extracellular traps (NETs) have been linked with the pathology of lung damage in 262 COVID-19(61). In line with this evidence, NETs, identified as extracellular DNA staining 263 colocalizing with neutrophil elastase (NE) and citrullinated histone H3 (H3Cit) by confocal 264 microscopy(63), were not found in lung of WT mice but present in parenchima and alveoli 265 of v-FLIP mice (Fig. 2e). Since several stimuli trigger neutrophil activation and NETosis, 266 including inflammatory cytokines and chemokines (64, 65), we evaluated whether myeloid 267 cells could be a source of these soluble factors. By intracellular staining, we enumerated 268 TNF- α - and IL-6-producing mononuclear (CD45.2⁺Ly6C⁺ cells) and polymorphonuclear 269 (CD45.2⁺Ly6G⁺ cells) cells isolated from the lung of vFLIP mice. We could not isolate 270 sufficient number of myeloid cells from WT mouse lungs. Inflammatory cytokine 271 production was higher in monocytes than in neutrophils (Fig. 2f). Notably, a marked 272 accumulation of myeloid cells was identified also in the spleen of vFLIP mice (Fig. 2g), in 273 which high percentages of pSTAT3⁺ and inflammatory cytokine-producing monocytes were 274 detected (Fig. 2h-i). We speculated that these cells might establish an unfavorable 275 environment for T cells and, indeed, effector and helper T cells were heavily contracted 276 while T regulatory lymphocytes (Tregs) significantly expanded in the spleen of vFLIP mice 277 (Supplementary information, Fig. S3b-c), unveiling a pronounced systemic lymphopenia 278 that mirrors COVID-19-associated CRS. 279

280

To gain broad insight into the immune landscape of CRS in vFLIP mice, we performed a single cell RNA sequencing (scRNA-seq) on lung-infiltrating cells. After preprocessing, integration and cell annotation (see Methods), a total of 31,274 mouse cell transcriptomes were obtained across WT and vFLIP mice. All the cells were visualized through t-

distributed stochastic neighbor embedding (t-SNE) assessing the cell proportions across 285 the different mouse samples to have a global overview of the cell composition 286 (Supplementary information, Fig. S4a-b). When we compared the percentage of each cell 287 type across WT and vFLIP conditions (Fig. 3a), vFLIP mice showed a higher proportion of 288 neutrophils (~65%) compared to WT mice (~23%) and a marked decrease in T (~5% 289 vFLIP; ~17% WT) and B lymphocytes (~3% vFLIP; ~21% WT), confirming the 290 aforementioned histopatological data about pulmonary infiltration of neutrophils (Fig. 2c). 291 Conversely, monocytes (~9% vFLIP; ~12% WT) and macrophages (~13% vFLIP; ~16% 292 WT) were comparable between the two groups. 293

294

To picture a global overview about biological pathways activated in vFLIP mice, we 295 performed gene set enrichment analysis (GSEA) comparing vFLIP and WT cells. We 296 noticed a significant up-regulation in inflammatory responses, TNF- α signaling via NF- κ B 297 and JAK-STAT3 signaling pathway that were among the top enriched gene sets (Fig. 3b). 298 Notably, these processes were related to the over-expression of several pro-inflammatory 299 mediators such as II1b, Ccrl2, II1a and Tnf (Fig. 3c). All these data are in line with results 300 about pSTAT3 overexpression and TNF- α hyper-production in vFLIP mice (Fig. 2f), as well 301 as previous data about FLIP controlling NF- κ B(35, 66). To link our results from vFLIP mice 302 with Sars-Cov-2 infection, we matched GSEA results obtained from vFLIP mice with GSEA 303 analysis of bulk RNA-Seq data of lung from hACE2 transgenic mouse infected with Sars-304 Cov-2(67). Comparing vFLIP up-regulated pathways with those enriched following 305 infection of hACE2 mice (day 7 post infection vs day 0, Fig. 3d), we found that SARS-CoV-306 2-induced inflammatory pathways were shared with vFLIP mice. Interestingly, these data 307 are in line with transcriptomic analysis using additional animal models of SARS-CoV-2 308 infection(68). 309

310

Together, these results support the concept that CRS syndrome in vFLIP mouse model may mimic COVID-19 immunopathology.

313

vFLIP mice and COVID-19 patients display similar inflammatory myeloid cell landscapes in pulmonary environment.

To compare the pulmonary immune landscape of vFLIP mice and COVID-19 patients, we 316 quantified the similarity between mouse lung-infiltrating leukocytes and 19,996 immune 317 cells isolated from bronchoalveolar lavage fluids (BAL) of severe COVID-19 patients (n=7; 318 WHO ordinal score 7) who were admitted to Intensive Care Units (ICU) of Verona 319 Hospital(32). A procedure similar to mouse cell integration and annotation was performed 320 in order to assess cell composition in human BAL samples (Supplementary information, 321 Fig. S4c-d). In both mouse and human datasets, neutrophils and monocyte/macrophage 322 populations were separated and re-integrated prior to clustering, in order to have a better 323 resolution in subset identification and comparison. 324

Following clustering, mouse neutrophils comprised 4 subsets characterized by canonical 326 neutrophil markers including S100-family genes and Adam8 (cluster 0), inflammatory 327 chemokines *Ccl3* and *Ccl4* (cluster 1), high expression of *Camp* and *Ngp* genes (cluster 2) 328 and interferon response genes Isg15/Isg20 (cluster 3) (Fig. 4a and Supplementary 329 information, Table S2). Similarly, in COVID-19 BAL, we outlined 5 different clusters 330 expressing marker genes similar to mouse neutrophil subsets. In particular, we observed 331 clusters expressing canonical neutrophil markers such as S100A8/S100A9 genes (cluster 332 a), CCL3/CCL4 chemokines as well as CTSB and CSTB genes (cluster b), interferon-333 response genes IFIT1, IFIT2 and ISG15/ISG20 (cluster c) and other 2 clusters expressing 334 ribosomal (cluster d) and heat shock protein (HSPs) genes (cluster e) (Fig. 4b and 335 Supplementary information, Table S2). 336

- We used reference-based classification (see Methods section) to map mouse subsets into 337 human subsets. The results confirmed a conserved structure among neutrophil clusters 338 between the two species and pathologies (Fig. 4c). In fact, about 89% of the human 339 340 cluster c was annotated as cluster 3 of mouse, about 81% of cluster d was annotated as cluster 1 and, finally, clusters a, b and e were mainly annotated as cluster 1 of mouse (60-341 65%). Conversely, cluster 2 appeared to be a mouse-specific neutrophil subset with no 342 relevant correspondence in human subsets. These results recapitulate published reports 343 (69), in which 3 conserved modules between mouse and human were characterized by the 344 expression of *Ccl3/CCL3*, *Cstb/CSTB* (cluster 1 in vFLIP), type I interferon response genes 345 such as Ifit1/IFIT1, Irf7/IRF7 and Rsad2/RSAD2 (cluster 3 in vFLIP), and neutrophils 346 expressing canonical markers S100a8-a9/S100A8-A9 (cluster 0 in vFLIP). 347
- 348

Even though mouse clusters 1 and 3 were not the most abundant neutrophil subsets (Fig. 349 4a) in vFLIP mice, they were the most dysregulated in terms of cell proportion compared 350 to WT. Indeed, Cluster 1 displayed more than 2-fold increase (~27% vFLIP; ~11% WT) 351 while cluster 3 about 3-fold decrease in vFLIP compared to WT (~3% vFLIP; ~1% WT). 352 Furthermore, GSEA analysis at the cluster level revealed several leading genes involved in 353 neutrophil inflammatory response in cluster 1 (Supplementary information, Table S2), such 354 as *Il1b*, *Ifitm1*, *Clec5A* and *Ccrl2*, which were up-regulated in vFLIP compared to WT mice 355 (Fig. 4d and Supplementary information, Table S2). 356

357

We detected 7 clusters mononuclear phagocyte compartment 358 in mouse (monocytes/macrophages) (Fig. 4e). Among macrophages we could identify alveolar 359 macrophages expressing *Mrc1*, *Krt79* and *Krt19* genes (cluster 0), macrophages 360 expressing either inflammatory cytokines such as Cxcl3, Cxcl1 and Il1a (cluster 4) or 361 proliferation markers Mki67 and Top2a (cluster 5), and a cluster expressing high levels of 362 ribosomal genes (Cluster 6). In addition, we obtained a cluster composed by both 363 macrophages (~64%) and monocytes (~36%) characterized by the expression of *C1ga* 364 and *C1qb* (cluster 1). Finally, among monocytes we detected classical monocytes 365 expressing Ccr2 and Ly6c2 (cluster 3) and non-classical monocytes expressing Ly6c2, Ace 366

and Cd300e (cluster 2), reproducing the immune landscape previously described in tumor-367 bearing mice(69). In monocytes/macrophages compartment from BAL patients, we 368 observed 5 clusters (Fig. 4f): a macrophage cluster expressing proliferation markers 369 MKI67 and TOP2A (cluster d); a cluster characterized mainly by macrophages expressing 370 CIQA, CIQB and MRC1 (cluster a); a cluster expressing monocyte markers FCN1 and 371 372 VCAN (cluster b); two small clusters expressing ribosomial (cluster c) and heat shock protein (HSPs) genes (cluster e). Probably due to the intrinsic complexity(69) and the low 373 number of cells in the mononuclear phagocyte compartment(32), we were not able to 374 distinguish classical from non-classical monocytes as well as to identify different 375 macrophage subsets in BAL samples. Therefore, unlike neutrophils, we could not 376 377 reconstruct an effective map between mouse and human monocyte/macrophage subsets. However, we observed the expression of similar top marker genes between subset 5 and 378 d, which identified proliferating macrophages (Supplementary information, Table S2); 379 furthermore, the expression of several macrophage lineage genes such C1OA, C1OB and 380 MRC1 was shared between the two species. Conversely, inflammatory genes such as IL1B, 381 CXCL1 and CXCL3 were mainly expressed by monocytes in BALs, unlike mouse dataset in 382 which they were expressed at high levels both in monocyte and macrophages 383 (Supplementary information, Table S2). Through gene set variation analysis (GSVA), we 384 confirmed that inflammatory response and related pathways TNF- α signaling via NF- κ B 385 and JAK-STAT3 signaling were active in several clusters of mouse monocytes and 386 macrophages while in BALs were specifically localized in monocytes (Fig. 4g). Despite 387 several mouse subsets presented an up-regulation of inflammatory genes in vFLIP 388 compared to WT mice (Fig. 4h, top panels) as well as high GSVA scores on inflammatory-389 related pathways (Fig. 4g), GSEA analysis at the cluster level unveiled significant up-390 regulation of inflammatory response, TNF- α signaling via NF- κ B and JAK-STAT3 pathways 391 specifically in cluster 4 (Supplementary information, Table S2), which was also the most 392 dysregulated in terms of cell proportion (~19% vFLIP; ~8% WT) (Fig. 4e). Notably, the 393 up-regulation of JAK-STAT3 signaling pathway, in vFLIP cluster 4 compared to WT, was 394 paralleled by the expression of several genes in the pathway such as Jak2, Csf1, Il10rb 395 396 and *Cd38* (Fig. 4h, bottom panels).

397

In summary, a conserved landscape of myeloid cells enriched for transcriptional signatures associated with the inflammatory response was detailed in the lung environment of both vFLIP mice and severe COVID-19 patients, in line with the concept that FLIP-expressing myeloid cells drive lung pathology.

402

403 STAT3 targeting restrains immunopathology in vFLIP mice.

To investigate whether targeting STAT3 could be sufficient to dampen the uncontrolled immune dysregulation in vFLIP mice, we evaluated therapeutic approaches involving either pharmacological or RNA interference of STAT3. Initially, we tested *in vivo* the efficacy of two STAT3 inhibitors: silibinin, a STAT3 inhibitor that blocks the Y705 phosphorylation-

related and STAT3 dimerization(70), or baricitinib, a clinically-approved inhibitor of JAK1 408 and JAK2 able to interfere with STAT3 signaling activation(71). Four weeks after the 409 establishment of BM chimerism in recipients (T0), mice were treated every two days by 410 intraperitoneal injection. Weight loss was significantly decreased in mice that had received 411 the drug treatments (Supplementary information, Fig. S5a). Furthermore, STAT3 targeting 412 reduced the plasma concentration of several pro-inflammatory cytokines (Fig. 5a), which 413 are produced at abnormal levels in untreated vFLIP mice and are also a feature of COVID-414 19(3). Immunohistochemistry of spleen demonstrated a reduction in systemic 415 lymphopenia of treated vFLIP mice, with some differences, since baricitinib furthered a 416 raise in both T and B cells while silibinin affected only T lymphocyte frequency (Fig. 5b). 417 By analyzing eight different parameters (e.g. interstitial enlargement, vascular congestion, 418 perivascular neutrophils, presence of thrombi, presence of infarction, fibroplasia, foam cell 419 clusters and perivascular infiltrate; Supplementary information, Fig. S5b), we confirmed a 420 reduction in the pathological score of inflammatory pneumonia in treated mice (Fig. 5c 421 422 and Supplementary information, Fig. S5c).

423

To explore further the molecular underpinnings of the inflammatory shutdown, we 424 evaluated the lung-infiltrating leukocyte profile of treated and untreated vFLIP mice by 425 scRNA-seq. After projecting the cells into a 2-dimensional space using t-SNE, we evaluated 426 the effect of pharmacological treatments on the proportions of the main cellular subsets. 427 Both treatments reduced the neutrophil proportion (~82% UT; ~76% silibinin; ~66% 428 baricitinib), with a compensatory increase in other cells, such as lymphocytes, indicating a 429 trend towards rebalancing the lung-infiltrating leukocyte frequency (Fig. 5d). Considering 430 neutrophil subgroups, we observed a slight reduction in the major neutrophil subset 431 (cluster 0: ~89% UT; ~87% silibinin; ~86% baricitinib) in treated mice and an expansion 432 in neutrophils expressing interferon-response genes (cluster 3: ~2% UT; ~4% silibinin: 433 ~5% baricitinib) (Supplementary information, Fig. S5d). Therefore, STAT3-targeting 434 approaches can alter neutrophil composition favoring the accrual of elements with type I 435 interferon response-associated genes. As for the monocytes/macrophages in treated mice, 436 we observed a decrease in both classical monocytes (clusters 3: ~32% UT; ~23% 437 silibinin; ~25% baricitinib) and macrophages expressing inflammatory cytokines (cluster 438 4: ~12% UT; ~8% silibinin; ~8% baricitinib); at the same time, we evinced the increase 439 in clusters 1 (~25% UT; ~27% silibinin; ~41% baricitinib) and cluster 2 (non-classical 440 monocytes: ~10% UT; ~20% silibinin; ~14% baricitinib) (Supplementary information, Fig. 441 S5d). 442

443

Finally, GSEA analysis confirmed an up-regulation of interferon alpha/gamma pathways in both STAT3-based treatments compared to controls and, simultaneously, the downregulation of gene signatures associated to inflammatory response, JAK-STAT3-dependent signaling pathways and TNF- α signaling via NF- κ B (Fig. 5e). Consistent with this effect, several inflammatory genes, such as *Il1b, Clec5a, Ccrl2* and *Ifitm1* were down-regulated

while *Ifitm3*, *Stat1* and *Isg15* genes, which are associated to interferon response pathways, were up-regulated in baricitinib-treated vFLIP mice (Fig. 5f). Thus, STAT3 inhibitors might mitigate the inflammatory pathology, both locally and systemically, by affecting the aberrant FLIPs-STAT3 feedforward loop while keeping the antiviral response active.

454

463

To confirm the immunomodulatory capacity of STAT3 inhibitors, we tested the ability of 455 these two compounds to control the immunosuppressive functions of c-FLIP-expressing 456 monocytes isolated from COVID-19 patients. T cell proliferation was significantly preserved 457 after co-culture with monocytes pre-treated with the two drugs, as compared to untreated 458 controls (Supplementary information, Fig. S5e). These results indicate that STAT3-459 targeting may prevent T cell dysregulations by limiting immunosuppressive features of 460 SARS-CoV-2-educated myeloid cells, endorsing the clinical results about baricitinib efficacy 461 in altering immunoregulatory properties of myeloid cells in COVID-19 patients(59). 462

To provide complementary evidence that a direct STAT3-silencing in myeloid cells could 464 control the evolution of immunopathological disorders in vFLIP mice, we exploited the in 465 vivo delivery of 4PD nanoparticles loaded with STAT3-specific short hairpin RNAs 466 (shSTAT3) on their surface. The ability of 4PDs to recognize and target preferentially 467 mononuclear phagocytes and mediate an effective in vivo delivery of shSTAT3 was 468 previously proven in cancer mouse models(72). Therefore, vFLIP mice were treated by a 469 total of nine administrations, every two days, of 4PDs loaded with either a scrambled RNA 470 sequence (shCTRL, as negative control) or shSTAT3. Similar to STAT3 pharmacological 471 treatment, the genetically-based STAT3 silencing in myeloid compartment controlled the 472 weight loss, limiting CRS-associated cachexia (Supplementary information, Fig. S6a). 473 Moreover, STAT3-silencing affected the severity of inflammatory pneumonia, as 474 highlighted by the decrease in lung pathological score (Fig. 6a and Supplementary 475 information, Fig. S6b) and allowed a complete contraction of neutrophilia in pulmonary 476 tissues (Fig. 6b and Supplementary information, Fig. S6c). Notably, shSTAT3 treated mice 477 showed also a reduction in systemic lymphopenia, with an increased frequency of both T 478 and B lymphocytes and a concomitant myeloid cell reduction in the spleen (Fig. 6c) and in 479 peripheral blood (Fig. 6d). Finally, the 4PD-mediated, STAT3-specific shRNA delivery 480 normalized the plasma concentration of several pro-inflammatory cytokines (Fig. 6e). 481

482

Taken together, these data indicate that STAT3-targeting, especially in myeloid cells, is effective in tempering CRS-associated immunopathological disorders triggered by the accumulation of FLIP-expressing cells.

486

487 **Discussion**

To date, the pathology of CRS is incompletely understood and no single definition is widely 489 accepted by the scientific community. Our data establish FLIP-expressing myeloid cells as 490 a pivotal driver of CRS. Indeed, the vFLIP chimera mice show acute systemic inflammatory 491 symptoms (Fig. 2 and Supplementary information, Fig. S2-3), elevated cytokine levels 492 (Fig. 5a), weight loss (Supplementary information, Fig. S5a), lymphopenia (Supplementary 493 information, Fig. S2c), lung injury (Fig. 2a) endothelial cell activation (Fig. 2d) and 494 multiple organ dysfunctions (Supplementary information, Fig. S2d). The impact of vFLIP 495 activation on building up inflammatory diseases is confirmed also by evidence about the 496 role of this anti-apoptotic protein in inflammatory bowel disease(73), multicentric 497 Castleman disease in mice(74), as well as on reprogramming myeloid cells into 498 499 immunosuppressive elements in cancer(35).

A significant gap remains between pre-clinical testing and clinical trials to treat efficiently 501 CRS, as well as to identify key molecular mechanisms that control the pathogenic process. 502 503 In the last decades, mouse models of sepsis, such as LPS-induced inflammation, or the development of humanized mice based on the engraftment of human PBMCs into 504 immunodeficient mice, which mimic CAR T-cell therapy-induced cytokine storm, have been 505 primarily developed to replicate clinical stages and outcomes of CRS, as platforms for 506 screening potential therapies (6, 75). However, no suitable and appropriate experimental in 507 vivo models have been developed to identify alterations in molecular and cellular 508 processes that might highlight the triggers of CRS. Our study based on a tissue-specific 509 transgenic, conditional knock-in mouse model offer a novel tool for defining the 510 mechanisms that fuel inflammation and CRS-associated immune dysfunctions. 511

512

500

In line with our results, recent studies underlined that c-FLIP expression was enhanced in 513 several SARS-CoV-2 infected cell lines, where the expression of FLIP suppressors, such as 514 the forkhead transcriptional factor FoxO3A(76), was abrogated(30, 77). Since the 515 interaction of c-FLIP to FADD and/or caspase-8 or -10 and TRAIL receptor 5 prevents 516 death-inducing signaling complex formation and subsequent activation of the caspase 517 cascade(78), it is plausible that SARS-CoV-2 virus exploits FLIP-mediated cell death delay 518 for its own replication. Our analysis of both SARS-CoV-2-infected hACE2 transgenic mice 519 and autopsy samples from lung in COVID-19 patients demonstrated, for the first time, the 520 in vivo overexpression of FLIP in myeloid cells in severe COVID-19 (Fig. 1). However, 521 compared to the traditionally ascribed FLIP intervention on cell-survival, our findings 522 rather point to the additional function of modulating myeloid cells to determine CRS 523 progression (Fig. 1d-e; Fig. 2i). 524

525

526 Monocytes from both COVID-19 patients (Fig. 1c) and vFLIP transgenic mice(*35*) display 527 immunosuppressive properties and are a source of pro-inflammatory cytokines (Fig. 1e 528 and Supplementary information, Fig. S1d). We found that immunoregulatory functions of 529 monocytes isolated from COVID-19 patients correlated with the expression of PD-L1

(Supplementary information, Fig. S1c), suggesting a possible contribution of immune 530 checkpoint engagement on T cell blockade during COVID-19 evolution. These data are in 531 line with our previous findings showing that FLIP-expressing monocytes isolated from 532 PDAC patients had high levels of surface PD-L1(35) and confirm previous reports 533 indicating that immunosuppressive myeloid cells in COVID-19 patients did exhibit 534 increased CD274 mRNA levels(32, 34). In agreement with Schulte-Schrepping's report in 535 which STAT3 was suspected as transcriptional factor of immunosuppressive monocytes in 536 COVID-19, we demonstrated that immunosuppression by monocytes isolated from COVID-537 19 patients can be indeed reverted by STAT3 inhibitors (Supplementary information, Fig. 538 S5e). Furthermore, we unveiled a concomitant expression of FLIP and activated STAT3 539 signaling in myeloid cells of SARS-CoV-2 infected hosts (Fig. 1a and Fig. 1f), as well as in 540 vFLIP transgenic mouse model (Fig. 2c). Further investigations should mechanistically 541 address the unconventional properties of c-FLIP as transcription factor, either by itself or 542 cofactor of transcriptional machinery capable of activating STAT3 signaling pathway in 543 544 myeloid cells under pathological conditions, which to date are only partially demonstrated in immortalized cell lines(43, 79). 545

Since the in vitro enforced expression of FLIP in myeloid cells promotes the 547 overexpression of several pro-inflammatory cytokines (i.e. IL-6, IL-7, IL-10, CSF3 and 548 TNF- α) by a "steered" NF- κ B activation, which also results in enhanced STAT3-signalling 549 activation(35), we argue that a pervasive inflammatory loop is established by FLIP through 550 the joint action of NF-κB and STAT3 during CRS evolution. Indeed, a synergy between NF-551 κ B and STAT3 molecules based on pro-inflammatory cytokines (i.e. IL-6), which act as 552 inflammation amplifier, was reported in several multiple inflammatory and autoimmune 553 diseases(80) and postulated also in COVID-19(81). In agreement with this paradigm, a 554 recent analysis of multi-organ proteomic landscape of COVID-19 autopsies confirmed both 555 NF- κ B and STAT3 as transcription factors largely upregulated in multiple organs (82), 556 implying a widespread and pervasive activations of the two pathways. 557

558

546

Our *in vivo* findings show that STAT3-targeting provides a significant disease control in 559 mice with CRS, unexpectedly highlighting how blocking a single member of the NF-560 κ B/STAT3 loop is sufficient to halt pathological inflammation. Data presented here are in 561 line with recent clinical results about baricitinib efficacy in controlling SARS-CoV-2-562 mediated immune dysregulation (59, 68, 83, 84) and with the decision of U.S. Food and 563 Drug Administration to approve baricitinib in combination with remdesivir for the 564 treatment of severe COVID-19 patients. More important, we demonstrated that Jak1/Jak2 565 inhibitor did not affect negatively genes associated with type I IFN antiviral responses but, 566 on the contrary, pharmacological treatment was associated with a relative increase in 567 interferon-stimulated genes (Fig. 5e-f), likely by re-programming the myeloid composition 568 in the lung environment (Fig. 5d and Supplementary information, Fig. S5c). This signaling 569 switch might be due to the activity of STAT1 occupying space on STAT3-activating 570

receptors, as suggested by the conversion of IL-6R signaling to a dominant STAT1 activation in STAT3-deficient cells(*85, 86*). Finally, the striking results on the normalization of the immune landscape, organ pathology and cachexia following shSTAT3-based treatment (Fig. 6 and Supplementary information, Fig. S6) clearly finger at STAT3 as the main target in FLIP expressing myeloid cells and define it as the most deleterious cause of immune and tissue damage during CRS.

577

Despite the caveats linked to species-specific profiles, our findings revealed some 578 conserved genetic features of lung-infiltrating myeloid cells between vFLIP mice and 579 COVID-19 patients. Indeed, neutrophil subsets characterized by the expression of S100-580 family genes, type I interferon response genes (ISG15/ISG20) and chemokines 581 (*Ccl3/CCL3*), as well as macrophages expressing proliferation-associated gene signatures 582 (Mki67, Top2a) showed similarities among species. The shared leukocyte subsets showed 583 a higher expression of inflammatory response-associated genes and were more prone to 584 STAT3 therapy. 585

586

In summary, in this study we demonstrated the pivotal role of FLIP-expressing myeloid cells to stimulate directly a lethal inflammatory status, by fueling an aberrant STAT3dependent signaling pathway. Moreover, we substantiated the therapeutic effectiveness of STAT3 on-target strategy to mitigate uncontrolled inflammation and acute disease, which serve as a foundation for the development of more accurate and evidence-based therapies to control CRS disorders, as well as severe clinical aspects of the ongoing COVID-19 pandemic crisis.

594 595

596 Materials and Methods

597 *Study design for patients*

This study was designed to explore the impact of FLIP/STAT3 axis in promoting immunological alteration in COVID-19 patients. All 48 patients with COVID-19 and 4 healthy donors in this study were admitted, within the period from March 12th to April 20th 2020 to the University Hospital of Verona or Hospital of Pescara. At sampling, the stage of disease was categorized as mild (patients not requiring non- invasive/mechanical ventilation and/or admission to ICU) or severe (patients requiring admission to ICU and/or non-invasive/mechanical ventilation).

For immunohistochemistry analysis of lung autopsy, this study includes a group of 4 non respiratory disease (NDR) patients, 4 bacterial pneumonia (BD) patients and 23 COVID-19
 patients. The clinical features are recapitulated in Supplementary information, Table S1a b.

For molecular data (i.e. single cell transcriptomic analysis), phenotypic analysis (myeloid characterization in terms of expression of immune suppression hallmarks) and functional data (myeloid immune suppressive assay), this study includes a group of 14 severe COVID-19 patients admitted to ICU, 11 mild SARS-CoV-2 patients and 4 HDs. The clinical features of the 3 groups of subjects are recapitulated in Supplementary information, Table S1c.

All the patients (and/or initially their families) provided written informed consent before sampling and for the use of their clinical and biological data. This study was approved by the local ethical committee (protocol 17963; principal investigator, Vincenzo Bronte; ClinicalTrials.gov identifier NCT04438629). All clinical investigations were conducted according to Declaration of Helsinki principles, and informed consent was obtained from all study participants.

621 Study design for mice

This study was designed to define vFLIP+p-STAT3+ myeloid cells as a main driver for CRS 622 progression as well as to test STAT3-targeting approach as a possible strategy to 623 ameliorate CRS-undergoing hosts. All genetically transgenic mice and their respective 624 controls were gender and age-matched (typically 3-10 weeks) and both males and 625 females were used in this study. Mice were assigned randomly to experimental groups. 626 Germ free C57BL/6 mice were originally purchased from Charles River Laboratories Inc., 627 congenic mice (*B6.SJL-Ptrc^aPepc^b/BoyJ*) and LySM-CRE mice (*B6.129P2-*628 CD45.1⁺ Lyz2^{tm1(cre)Ifo}/J) were purchased from Jackson Laboratories; Rosa26.vFLIP mice were a gift 629 from Dr. Ethel Cesarman (Weill Cornell Medicine, NY, USA). 630

To generate the vFLIP-chimera mouse model (hereafter named vFLIP mice), C57BL/6 631 female of 8 weeks of age received 9 Gy total body irradiation (TBI) using ¹³⁷Cs-source 632 irradiator. Six hours after pre-conditioning, irradiated recipient mice were intravenously 633 injected with 5x10⁶ bone marrow cells obtained from CD45.1 WT and ROSAvFLIP Tg 634 (CD45.2) donor mice at different ratio. Bone marrow cells over-expressing FLIP protein 635 from Kaposi's sarcoma virus (v-FLIP) in myeloid compartment were collected from 636 ROSA26.vFLIP Tg knock-in mice. These mice were obtained by crossing ROSA26.vFLIP 637 knock-in mice with mice expressing Cre recombinase under control of the endogenous 638 Lyz2 promoter. For the therapeutic studies, 50% WT-50% vFLIP ratio was used to 639 generate the vFLIP-chimera mice. Four weeks post bone-marrow transplantation, 640 peripheral blood of recipient mice was analyzed for the presence of donor-derived cells. 641

The *in vivo* effect of drugs treatment was investigated in the vFLIP-chimera mouse model, four weeks after the bone marrow cells transplantation. Chimera mice that displayed at least 20% of donor-derived cells were randomized before beginning treatment. Chimera mice were treated using 8 intraperitoneal administrations of Baricitinib (10 mg/kg; Cayman chemicals) or Silibinin (100mg/kg; Sigma-Aldrich) every two days, for a total of 9

treatments. shRNA treatments were performed three times a week by injecting shRNA 647 (anti-STAT3 or scramble) loaded onto 4PD intravenously as previously described(72), for a 648 treatments. 5'shRNA STAT3 649 total of 9 sequence: UAAUACGACUCACUAUAAGGAGGGUGUCAGAUCACAUGGGCUUUCAAGAGAUCUCAACGGACC 650 5'-AUGCUACUGCCUU-3'; shRNA scramble STAT3 651 sequence: UAAUACGACUCACUAUAAGGGCAGUAGCAUGGUCCGUUGAGAUUCAAGAGAUCUCAACGGACC 652 AUGCUACUGCCUU-3' (Boston Open Labs). Immunohistochemistry (IHC) and flow 653 cytometry analysis were performed at the end of the experiment (2 weeks after the first 654 treatment). Chimera mice were euthanized when the weight loss reached the 20% of 655 body-weight as an animal protocol-defined endpoint. 656

All mice were maintained under specific pathogen-free conditions in the animal facility of 657 the University of Verona. Food and water were provided *ad libitum*. Animal experiments 658 were performed according to national (protocol number C46F4.26 approved by the 659 Ministerial Decree Number 993/2020-PR of July 24, 2020 (PI: Stefano Ugel) and protocol 660 number C46F4.8 approved by the Ministerial Decree Number 207/2018-PR of February 21, 661 2018) and European laws and regulations. All animal experiments were approved by 662 Verona University Ethical Committee and conducted according to the guidelines of 663 Federation of European Laboratory Animal Science Association (FELASA). All animal 664 experiments were in accordance with the Amsterdam Protocol on animal protection and 665 welfare: mice were monitored daily and euthanized when displaying excessive discomfort. 666

667 Statistical analysis

All data are reported as mean \pm standard error (SE) of the mean. Statistical analyses were performed using Graph Pad Prism (version 8.0.2). Student *t* test (parametric groups) and Wilcoxon–Mann–Whitney test (nonparametric groups) were used to determine statistical significance of differences between two treatment groups. Values were considered significant at $P \le 0.05$.

673

674

675 **References**

- 6761.J. W. Griffith, C. L. Sokol, A. D. Luster, Chemokines and chemokine receptors: positioning677cells for host defense and immunity. *Annu Rev Immunol* **32**, 659-702 (2014).
- 678 2. M. A. Rieger, P. S. Hoppe, B. M. Smejkal, A. C. Eitelhuber, T. Schroeder, Hematopoietic cytokines can instruct lineage choice. *Science* **325**, 217-218 (2009).
- 680 3. D. C. Fajgenbaum, C. H. June, Cytokine Storm. N Engl J Med **383**, 2255-2273 (2020).
- 6814.M. D. de Jong *et al.*, Fatal outcome of human influenza A (H5N1) is associated with high682viral load and hypercytokinemia. *Nat Med* **12**, 1203-1207 (2006).
- 5. T. van der Poll, S. M. Opal, Host-pathogen interactions in sepsis. *Lancet Infect Dis* 8, 32-43 (2008).
- 685 6. M. Norelli *et al.*, Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-686 release syndrome and neurotoxicity due to CAR T cells. *Nat Med* **24**, 739-748 (2018).

- T. Giavridis *et al.*, CAR T cell-induced cytokine release syndrome is mediated by
 macrophages and abated by IL-1 blockade. *Nat Med* 24, 731-738 (2018).
- A. E. Obstfeld *et al.*, Cytokine release syndrome associated with chimeric-antigen receptor
 T-cell therapy: clinicopathological insights. *Blood* **130**, 2569-2572 (2017).
- 9. U. Winkler *et al.*, Cytokine-release syndrome in patients with B-cell chronic lymphocytic
 leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal
 antibody (rituximab, IDEC-C2B8). *Blood* **94**, 2217-2224 (1999).
- D. T. Teachey *et al.*, Cytokine release syndrome after blinatumomab treatment related to
 abnormal macrophage activation and ameliorated with cytokine-directed therapy. *Blood* **121**, 5154-5157 (2013).
- R. Abboud *et al.*, Severe Cytokine-Release Syndrome after T Cell-Replete Peripheral Blood
 Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti-IL-6
 Therapy Is Safe and Well Tolerated. *Biol Blood Marrow Transplant* 22, 1851-1860 (2016).
- D. C. Fajgenbaum *et al.*, Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in
 IL-6-blockade-refractory idiopathic multicentric Castleman disease. *J Clin Invest* **129**, 4451 4463 (2019).
- 70313.S. K. Pierson *et al.*, Plasma proteomics identifies a 'chemokine storm' in idiopathic704multicentric Castleman disease. *Am J Hematol* **93**, 902-912 (2018).
- M. A. Matthay, L. B. Ware, G. A. Zimmerman, The acute respiratory distress syndrome. *J Clin Invest* **122**, 2731-2740 (2012).
- 70916.D. M. Studdert, M. A. Hall, Disease Control, Civil Liberties, and Mass Testing Calibrating710Restrictions during the Covid-19 Pandemic. N Engl J Med **383**, 102-104 (2020).
- 71117.C. Wang, P. W. Horby, F. G. Hayden, G. F. Gao, A novel coronavirus outbreak of global712health concern. Lancet **395**, 470-473 (2020).
- 71318.P. Zhou *et al.*, A pneumonia outbreak associated with a new coronavirus of probable bat714origin. *Nature* **579**, 270-273 (2020).
- 19. W. J. Guan *et al.*, Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* 382, 1708-1720 (2020).
- Z. Xu *et al.*, Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med* 8, 420-422 (2020).
- 719
 21.
 C. Doglioni
 et al., Acute
 Lung injury
 evolution
 in
 Covid-19.
 medRxiv,

 720
 2020.2008.2009.20170910 (2020).
- L. Carsana *et al.*, Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. *Lancet Infect Dis* 20, 1135-1140 (2020).
- D. McGonagle, J. S. O'Donnell, K. Sharif, P. Emery, C. Bridgewood, Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. *Lancet Rheumatol* 2, e437e445 (2020).
- 726 24. A. Gupta *et al.*, Extrapulmonary manifestations of COVID-19. *Nat Med* **26**, 1017-1032 (2020).
- 72825.Z. Varga *et al.*, Endothelial cell infection and endotheliitis in COVID-19. *Lancet* **395**, 1417-7291418 (2020).
- M. Ackermann *et al.*, Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. *N Engl J Med* 383, 120-128 (2020).
- P. Mehta *et al.*, COVID-19: consider cytokine storm syndromes and immunosuppression.
 Lancet **395**, 1033-1034 (2020).
- B. J. Barnes *et al.*, Targeting potential drivers of COVID-19: Neutrophil extracellular traps. *J Exp Med* **217**, (2020).
- J. Carvelli *et al.*, Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis. *Nature* 588, 146-150 (2020).

- 73830.D. Blanco-Melo *et al.*, Imbalanced Host Response to SARS-CoV-2 Drives Development of739COVID-19. *Cell* **181**, 1036-1045.e1039 (2020).
- 74031.J. L. Schultze, A. C. Aschenbrenner, COVID-19 and the human innate immune system. *Cell*,741(2021).
- P. Bost *et al.*, Deciphering the state of immune silence in fatal COVID-19 patients. *Nature Communications* 12, 1428 (2021).
- D. M. Del Valle *et al.*, An inflammatory cytokine signature predicts COVID-19 severity and survival. *Nat Med* 26, 1636-1643 (2020).
- J. Schulte-Schrepping *et al.*, Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell
 Compartment. *Cell* **182**, 1419-1440.e1423 (2020).
- A. Fiore *et al.*, Induction of immunosuppressive functions and NF-κB by FLIP in monocytes.
 Nat Commun 9, 5193 (2018).
- M. Thome *et al.*, Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death
 receptors. *Nature* **386**, 517-521 (1997).
- M. Irmler *et al.*, Inhibition of death receptor signals by cellular FLIP. *Nature* 388, 190-195 (1997).
- J. Sadek *et al.*, Modulation of virus-induced NF-κB signaling by NEMO coiled coil mimics.
 Nat Commun **11**, 1786 (2020).
- 75639.A. Golks, D. Brenner, P. H. Krammer, I. N. Lavrik, The c-FLIP-NH2 terminus (p22-FLIP)757induces NF-kappaB activation. J Exp Med 203, 1295-1305 (2006).
- 40. A. R. Safa, c-FLIP, a master anti-apoptotic regulator. *Exp Oncol* **34**, 176-184 (2012).
- J. L. Shisler, Viral and cellular FLICE-inhibitory proteins: a comparison of their roles in regulating intrinsic immune responses. *J Virol* 88, 6539-6541 (2014).
- R. Katayama *et al.*, Modulation of Wnt signaling by the nuclear localization of cellular FLIPJ. *J Cell Sci* 123, 23-28 (2010).
- 43. J. Zhang *et al.*, Nuclear localization of c-FLIP-L and its regulation of AP-1 activity. *Int J Biochem Cell Biol* **41**, 1678-1684 (2009).
- A. Roulston, R. C. Marcellus, P. E. Branton, Viruses and apoptosis. *Annu Rev Microbiol* 53, 577-628 (1999).
- K. Saito *et al.*, Hepatitis C virus core protein inhibits tumor necrosis factor alpha-mediated apoptosis by a protective effect involving cellular FLICE inhibitory protein. *J Virol* 80, 4372-4379 (2006).
- A. R. Lee *et al.*, Multiple Functions of Cellular FLIP Are Essential for Replication of Hepatitis
 B Virus. *J Virol* **92**, (2018).
- A. Krueger *et al.*, HTLV-1 Tax protects against CD95-mediated apoptosis by induction of
 the cellular FLICE-inhibitory protein (c-FLIP). *Blood* **107**, 3933-3939 (2006).
- 48. D. Gibellini *et al.*, HIV-1 Tat protein concomitantly down-regulates apical caspase-10 and up-regulates c-FLIP in lymphoid T cells: a potential molecular mechanism to escape TRAIL cytotoxicity. *J Cell Physiol* **203**, 547-556 (2005).
- 49. C. G. Tepper, M. F. Seldin, Modulation of caspase-8 and FLICE-inhibitory protein expression
 as a potential mechanism of Epstein-Barr virus tumorigenesis in Burkitt's lymphoma. *Blood*94, 1727-1737 (1999).
- 50. I. G. Rodrigue-Gervais *et al.*, Cellular inhibitor of apoptosis protein cIAP2 protects against
 pulmonary tissue necrosis during influenza virus infection to promote host survival. *Cell Host Microbe* 15, 23-35 (2014).
- 783 51. R. Nienhold *et al.*, Two distinct immunopathological profiles in autopsy lungs of COVID-19.
 784 *Nat Commun* **11**, 5086 (2020).
- 52. G. Rossi *et al.*, The role of macrophages in interstitial lung diseases: Number 3 in the Series
 "Pathology for the clinician" Edited by Peter Dorfmuller and Alberto Cavazza. *Eur Respir Rev* 26, (2017).

- 78853.M. Duan, M. L. Hibbs, W. Chen, The contributions of lung macrophage and monocyte789heterogeneity to influenza pathogenesis. Immunol Cell Biol **95**, 225-235 (2017).
- R. Trovato *et al.*, Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3. *J Immunother Cancer* **7**, 255 (2019).
- 55. S. Ugel, S. Cane, F. De Sanctis, V. Bronte, Monocytes in the Tumor Microenvironment.
 Annu Rev Pathol 16, 93-122 (2021).
- D. Vasquez-Dunddel *et al.*, STAT3 regulates arginase-I in myeloid-derived suppressor cells
 from cancer patients. *J Clin Invest* **123**, 1580-1589 (2013).
- 79757.H. Yu, D. Pardoll, R. Jove, STATs in cancer inflammation and immunity: a leading role for798STAT3. Nat Rev Cancer 9, 798-809 (2009).
- 799 58. M. Merad, J. C. Martin, Pathological inflammation in patients with COVID-19: a key role for 800 monocytes and macrophages. *Nat Rev Immunol* **20**, 355-362 (2020).
- 80159.V. Bronte *et al.*, Baricitinib restrains the immune dysregulation in patients with severe802COVID-19. J Clin Invest **130**, 6409-6416 (2020).
- 80360.R. D. Jiang *et al.*, Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human804Angiotensin-Converting Enzyme 2. *Cell* **182**, 50-58.e58 (2020).
- 80561.F. P. Veras *et al.*, SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19806pathology. J Exp Med **217**, (2020).
- B. E. Hallahan, M. J. Staba-Hogan, S. Virudachalam, A. Kolchinsky, X-ray-induced P-selectin
 localization to the lumen of tumor blood vessels. *Cancer Res* 58, 5216-5220 (1998).
- E. A. Middleton *et al.*, Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. *Blood* **136**, 1169-1179 (2020).
- 81164.V. Brinkmann *et al.*, Neutrophil extracellular traps kill bacteria. Science **303**, 1532-1535812(2004).
- 813 65. R. S. Keshari *et al.*, Cytokines induced neutrophil extracellular traps formation: implication 814 for the inflammatory disease condition. *PLoS One* **7**, e48111 (2012).
- M. Thome, J. Tschopp, Regulation of lymphocyte proliferation and death by FLIP. *Nat Rev Immunol* 1, 50-58 (2001).
- E. S. Winkler *et al.*, SARS-CoV-2 infection of human ACE2-transgenic mice causes severe
 lung inflammation and impaired function. *Nat Immunol* **21**, 1327-1335 (2020).
- 81968.T. N. Hoang *et al.*, Baricitinib treatment resolves lower-airway macrophage inflammation820and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques. *Cell*, (2020).
- 82169.R. Zilionis *et al.*, Single-Cell Transcriptomics of Human and Mouse Lung Cancers Reveals822Conserved Myeloid Populations across Individuals and Species. Immunity **50**, 1317-8231334.e1310 (2019).
- 824
 70.
 S. Verdura *et al.*, Silibinin is a direct inhibitor of STAT3. *Food Chem Toxicol* **116**, 161-172

 825
 (2018).
- J. J. O'Shea, S. M. Holland, L. M. Staudt, JAKs and STATs in immunity, immunodeficiency,
 and cancer. *N Engl J Med* **368**, 161-170 (2013).
- S. Zilio *et al.*, 4PD Functionalized Dendrimers: A Flexible Tool for In Vivo Gene Silencing of Tumor-Educated Myeloid Cells. *J Immunol* **198**, 4166-4177 (2017).
- 830 73. B. Ruder *et al.*, Chronic intestinal inflammation in mice expressing viral Flip in epithelial 831 cells. *Mucosal Immunol* **11**, 1621-1629 (2018).
- 832 74. G. Ballon, K. Chen, R. Perez, W. Tam, E. Cesarman, Kaposi sarcoma herpesvirus (KSHV)
 833 vFLIP oncoprotein induces B cell transdifferentiation and tumorigenesis in mice. *J Clin*834 *Invest* 121, 1141-1153 (2011).
- R. Karki *et al.*, Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue
 Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes. *Cell*,
 (2020).

- S. J. Park, H. Y. Sohn, J. Yoon, S. I. Park, Down-regulation of FoxO-dependent c-FLIP
 expression mediates TRAIL-induced apoptosis in activated hepatic stellate cells. *Cell Signal*21, 1495-1503 (2009).
- 77. J. Sun *et al.*, Comparative Transcriptome Analysis Reveals the Intensive Early Stage
 Responses of Host Cells to SARS-CoV-2 Infection. *Frontiers in Microbiology* **11**, (2020).
- 78. A. R. Safa, Roles of c-FLIP in Apoptosis, Necroptosis, and Autophagy. *J Carcinog Mutagen*Suppl 6, (2013).
- A. Adamo *et al.*, Moonlighting Proteins Are Important Players in Cancer Immunology. *Front Immunol* **11**, 613069 (2020).
- 847 80. M. Murakami *et al.*, Disease-association analysis of an inflammation-related feedback loop. 848 *Cell Rep* **3**, 946-959 (2013).
- 849 81. T. Hirano, M. Murakami, COVID-19: A New Virus, but a Familiar Receptor and Cytokine 850 Release Syndrome. *Immunity* **52**, 731-733 (2020).
- 851 82. X. Nie *et al.*, Multi-organ proteomic landscape of COVID-19 autopsies. *Cell* **184**, 775-791 e714 (2021).
- 853 83. J. Stebbing *et al.*, JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates 854 inflammatory responses to reduce morbidity and mortality. *Sci Adv*, (2020).
- 84. A. C. Kalil *et al.*, Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. *N Engl J Med*, (2020).
- 857 85. Y. Qing, G. R. Stark, Alternative activation of STAT1 and STAT3 in response to interferon-858 gamma. *J Biol Chem* **279**, 41679-41685 (2004).
- 86. P. J. Murray, The JAK-STAT signaling pathway: input and output integration. *J Immunol* **178**, 2623-2629 (2007).
- 87. K. R. Cooke *et al.*, An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. *Blood* 88, 3230-3239 (1996).
- 864
 88. A. Butler, P. Hoffman, P. Smibert, E. Papalexi, R. Satija, Integrating single-cell transcriptomic data across different conditions, technologies, and species. *Nat Biotechnol* 36, 411-420 (2018).
- 867 89. C. Hafemeister, R. Satija, Normalization and variance stabilization of single-cell RNA-seq 868 data using regularized negative binomial regression. *Genome Biol* **20**, 296 (2019).
- 869 90. T. Stuart *et al.*, Comprehensive Integration of Single-Cell Data. *Cell* **177**, 1888-1902 e1821
 870 (2019).
- 91. S. L. Wolock, R. Lopez, A. M. Klein, Scrublet: Computational Identification of Cell Doublets
 in Single-Cell Transcriptomic Data. *Cell Syst* 8, 281-291 e289 (2019).
- 92. D. Aran *et al.*, Reference-based analysis of lung single-cell sequencing reveals a transitional
 profibrotic macrophage. *Nat Immunol* **20**, 163-172 (2019).
- 93. T. S. Heng, M. W. Painter, C. Immunological Genome Project, The Immunological Genome
 Project: networks of gene expression in immune cells. *Nat Immunol* 9, 1091-1094 (2008).
- 877 94. B. A. Benayoun *et al.*, Remodeling of epigenome and transcriptome landscapes with aging
 878 in mice reveals widespread induction of inflammatory responses. *Genome Res* 29, 697-709
 879 (2019).
- 880 95. X. Han *et al.*, Mapping the Mouse Cell Atlas by Microwell-Seq. *Cell* **172**, 1091-1107 e1017 881 (2018).
- 96. J. H. Martens, H. G. Stunnenberg, BLUEPRINT: mapping human blood cell epigenomes. *Haematologica* **98**, 1487-1489 (2013).
- 884 97. N. de Souza, The ENCODE project. *Nat Methods* **9**, 1046 (2012).
- 98. N. A. Mabbott, J. K. Baillie, H. Brown, T. C. Freeman, D. A. Hume, An expression atlas of
 human primary cells: inference of gene function from coexpression networks. *BMC Genomics* 14, 632 (2013).

- 88899.G. Monaco *et al.*, RNA-Seq Signatures Normalized by mRNA Abundance Allow Absolute889Deconvolution of Human Immune Cell Types. *Cell Rep* **26**, 1627-1640 e1627 (2019).
- 100. G. Korotkevich *et al.*, Fast gene set enrichment analysis. *bioRxiv*, 060012 (2021).
- A. Subramanian *et al.*, Gene set enrichment analysis: a knowledge-based approach for
 interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A* **102**, 15545-15550
 (2005).
- 894 102. S. Hanzelmann, R. Castelo, J. Guinney, GSVA: gene set variation analysis for microarray
 895 and RNA-seq data. *BMC Bioinformatics* 14, 7 (2013).
- M. I. Love, W. Huber, S. Anders, Moderated estimation of fold change and dispersion for
 RNA-seq data with DESeq2. *Genome Biol* **15**, 550 (2014).
- A. Liberzon *et al.*, The Molecular Signatures Database (MSigDB) hallmark gene set collection. *Cell Syst* 1, 417-425 (2015).
- 900105.H. Wickham, in Use R!,. (Springer International Publishing : Imprint: Springer,, Cham,9012016), pp. 1 online resource (XVI, 260 pages 232 illustrations, 140 illustrations in color.
- 902
- 903 904

905 Acknowledgments

906

We thank Silvia Sartoris, Rosalinda Trovato, Varvara Petrova, Laura Pinton, Monica 907 Castellucci, Tommaso Grandi and Gianmarco Tarquini for their support and helpful 908 discussion during the development of this research. We thank Giulio Fracasso, Ornella 909 Poffe, Cristina Anselmi and Tiziana Cestari for perfect technical assistance. We thank 910 911 Pierre Bost, David Eyal, Jimmy Caroli, Oriana Romano and Mattia Forcato for bioinformatics support. We deeply acknowledge the contribution of 'Centro Piattaforme 912 Tecnologiche' of the University of Verona for sorting and imaging experiments and 'Centro 913 Interdipartimentale di Servizio alla Ricerca Sperimentale' of the University of Verona for 914 maintaining mouse colonies. We thank Ethel Cesarman (Weill Cornell Medical College, New 915 York, NY, USA) for the gift of the Rosa26.vFLIP conditional allele mice. We also thank all 916 the personnel involved in the patients' care and assistance; in particular, we thank Sara 917 Boschetti, Francesca Del Favero, Riccardo Boetti, Pasquale De Nardo, Fabiana Busti, 918 Chiara Mozzin, Federica Marola and Valentina Albanese. We wish to thank all the members 919 of the Immunology section of Department of Medicine of University of Verona who worked 920 forcefully during pandemic. We dedicate this work to the memory of the health care 921 922 workers who have given their lives in the care of patients with COVID-19.

- 923
- 924

925 Funding sources

926

This work was jointly supported by both S. Ugel grants of the Fondazione Italian Association for Cancer Research (AIRC, MFAG project: 21509) and PRIN program of Italian Ministry of Education, University and Research (MIUR, CUP: B38D19000140006) and V. Bronte grants funded by Fondazione Cariverona (ENACT Project), Fondazione TIM

931 (Immunovid Project), Fondazione AIRC (23788), Cancer Research Institute (Clinic and
932 Laboratory Integration Program, CLIP 2020), European Research Commission
933 (Euronanomed III, Joint Traslational Call_2017, Project RESOLVE) and MIUR (CUP:
934 B38D19000260006).

935

936 Author Contributions

- 937
- 938 Conceptualization: C.M., Si.C., A.F., V.B., S.U.;
- 939 Methodology: C.M., Si.C., A.F. and S.U.;
- Investigation: C.M., Si.C., A.F., C.F., F.D.S., St.C., A.A., F.H., R.M.B. and S.U.;
- 941 Immunohistochemistry and pathology analysis, data interpretation: A.L., F.D.P. and M.I.;
- 942 Computational analysis and data interpretation: Si.C., A.G. and S.B.;
- 943 Methodology for the in vivo RNA delivery experiments and data interpretation: S.Z. and 944 P.S.;
- 945 Responsible for biological specimens and patients' data collection: E.T., K.D., L.G., E.P.,
- 946 D.G., I.P., P.A.I., D.A. and A.C;
- 947 Methodology of human ACE2 mouse model, pathological analysis and data interpretation: 948 Y.C. and Z.L.S.
- 949 Writing and data interpretation: P.J.M, M.C. and I.A., V.B and S.U.;
- 950 Supervision: V.B. and S.U.;
- 951 Funding acquisition: V.B. and S.U.
- 952

953 Conflict of Interest

954

A.F., S.U. and V.B. hold proprietary rights on the patent applications about engineered cells for inducing tolerance by BioNTech (Mainz, Germany). S.Z., V.B. and P.S. hold proprietary rights on the patent applications about 4PD technology by University of Miami (Miami, U.S.A.). No potential conflicts of interest were disclosed by the other authors.

959



962 Fig. 1. c-FLIP and pSTAT3 expression in SARS-CoV-2-infected hosts.

(A) Representative H&E-stained microscopy images of lung tissue of non-respiratory 963 disease (NDR), bacterial pneumonia (BD) and COVID-19 patients (upper panel). Scale bar, 964 200 µm. Representative immunofluorescence (IF) staining of alveolar macrophages 965 (second, third and fourth lines) and histiocytic cells (fifth and sixth lines). Cells were 966 stained for CD68 (green), c-FLIP (red), pSTAT3 (white) and nuclei (blue). Scale bar, 20 967 µm. (B) Quantification and representative IF staining of c-FLIP in monocytes purified from 968 healthy donors (HD, n=4) or COVID-19 patients (n=5). Cells were stained for nuclei (blue) 969 and c-FLIP (red). Scale bar, 10 µm. (C) Correlation between percentage of suppression 970 and c-FLIP expression of circulating monocytes isolated from COVID-19 patients (n=16). 971 (D) Correlation between pSTAT3 and c-FLIP expression in circulating CD14⁺ cells isolated 972 from COVID-19 patients (n=10). (E) Correlation between the release of IL-6 or TNF- α 973 cytokines and pSTAT3 expression in circulating CD14⁺ cells from HD (red, n=4) and 974 COVID-19 patients (black, n=13). (F) Representative hematoxylin and eosin (H&E)-975 stained microscopy images of lung tissue of HFH4-hACE2 transgenic mice SARS-CoV-2-976 infected or mock-infected mice. Scale bar, 200 µm. pSTAT3, c-FLIP and CD11b expression 977 levels were detected by indirect immunofluorescence (IFA) staining. Scale bar, 100 µm. 978 979 Correlation analysis was performed by Spearman's rank correlation (C, D, E).



981 Fig. 2. Local and systemic pSTAT3-dependent inflammation in vFLIP mice.

(A) Representative H&E-stained microscopy images of lung of WT (upper panel) or vFLIP 982 chimera mice. Scale bar, 200 µm. (B) Representative IF staining of lung-infiltrating 983 neutrophils and macrophages in WT or vFLIP mice. Cells were stained for DAPI (blue), 984 neutrophil elastase (NE) (red, middle panel) and F4/80 (green, bottom panel). Scale bar, 985 200 µm. (C) Representative IF staining of lung-infiltrating neutrophils and macrophages in 986 WT or vFLIP mice. Scale bar, 20 µm. Cells were stained for DAPI (blue), NE (red, middle 987 panel) or F4/80 (green, bottom panel) and pSTAT3 Tyr705 (grey). (D) CD62P presence in 988 lung of WT (upper panel) or vFLIP mice by H&E staining. Scale bar, 100 µm. (E) 989 Representative confocal analysis of NET in WT (left panel; 50 µm) or vFLIP mice (200 990 µm). Cells were stained for DAPI (white), NE (red) and H3cit (blue). (F) Dot plots of IL-6 991 and TNF- α in lung-infiltrating mononuclear (CD45.2⁺Ly6C⁺ cells) and polymorphonuclear 992 (CD45.2+Ly6G+ cells) cells isolated from vFLIP mice (n=17). (G) Representative IF 993 staining of spleen-infiltrating neutrophils (NE⁺ cells) and monocytes/macrophages (F4/80⁺ 994 cells) in WT or vFLIP mice. Cells were stained for DAPI (blue), NE (red, middle panel) and 995 F4/80 (green, bottom panel). Scale bar, 200 µm. (H) Representative IF staining of spleen-996 infiltrating neutrophils and macrophages in WT or vFLIP mice. Cells were stained for DAPI 997 (blue), NE (red, middle panel) or F4/80 (green, bottom panel) and pSTAT3 Tyr705 (grey). 998 (I) Dot plots of IL-6 and TNF- α in myeloid cells in spleen of WT (n=8) or vFLIP mice 999 (n=9). Data are reported as mean \pm S.E.M. *p \leq 0.05, **p \leq 0.01 and ***p \leq 0.001 by 1000 Mann–Whitney test. 1001



1003 Fig. 3. Lung immune landscape in vFLIP mice affected by cytokine release 1004 syndrome.

(A) tSNE representation of scRNA-seq from 2 WT and 2 vFLIP mice samples (WT: 9,174; 1005 vFLIP: 9,847) colored according to cell type. Stacked bar plots representing cell type 1006 proportions across WT and vFLIP conditions. (B) Bar plot representing the up-regulated 1007 (NES > 0, adjusted p-value < 0.05) hallmark gene sets in the analysis of vFLIP vs WT cells 1008 obtained through GSEA analysis. (C) Violin plots showing the expression of key genes that 1009 drive the up-regulation of inflammatory response, TNF- α signaling via NF- κ B and JAK-1010 STAT3 signaling pathway in the lung of vFLIP mice. The asterisks denote statistically 1011 significant up-regulation in the comparison between vFLIP and WT conditions (*p < 0.05, 1012 **p < 0.01, ***p < 0.001). (D) Bar plot representing the up-regulated (NES > 0, 1013 adjusted p-value < 0.05) hallmark gene sets in bulk RNA-seg data obtained through GSEA 1014 analysis of ACE2-transgenic mice infected with Sars-CoV-2 (Winkler et al., 2020) 1015 comparing day 7 post infection (dpi) with mock-infected (0 dpi). Red bars refer to the 1016 gene sets enriched in both vFLIP and ACE2-transgenic mice. 1017

1018

1019

1020



Fig. 4. Unbiased comparison between lung-infiltrating cells of vFLIP mice and BAL-derived immune cells obtained from COVID-19 patients.

(A) tSNE representation and stacked bar plot showing cluster analysis of neutrophils 1025 coming from scRNA-seg analysis of lung tissue of mice (n=7) and **(B)** COVID-19 patients 1026 BALs (n=7). Neutrophils of mouse (17,099) and human (15,366) are visualized through 1027 tSNE projection and colored according to cluster analysis. (C) Reference-based 1028 classification of BAL neutrophil clusters using average expression of mice neutrophil 1029 clusters (see Methods). (D) Violin plots showing the expression of key inflammatory and 1030 interferon response genes among mouse neutrophil clusters. The asterisks denote 1031 statistically significant up-regulation in the comparison between vFLIP and WT conditions 1032 (*p < 0.05, **p < 0.01, ***p < 0.001). **(E)** Subset analysis of monocytes/macrophages 1033 of mouse (n = 7) and **(F)** COVID-19 BALs (n = 7). Monocytes/macrophages of mouse 1034 (6,115) and human (3,445) are visualized through tSNE projection and colored according 1035 to cluster analysis. (G) GSVA scores for inflammatory response, JAK-STAT3 signaling and 1036 TNF-α signaling via NF-κB pathway across mouse (left) and BAL (right) 1037 monocytes/macrophage clusters. (H) Violin plots showing the expression level of key 1038 inflammatory response and JAK-STAT3 signaling pathway genes across mouse 1039 monocytes/macrophages subsets. The asterisks denote statistically significant up-1040 regulation in the comparison between vFLIP and WT conditions (*p < 0.05, **p < 0.01, 1041 ***p < 0.001). 1042



1044 Fig. 5. STAT3 pharmacological targeting reduces lung damage and immune 1045 dysfunctions in vFLIP mice.

(A) Analysis of cytokines levels in serum of vFLIP mice before treatment (T0) or at the 1046 end of treatment (untreated, n=9; silibinin, n=9; baricitinib, n=9). (B) Lymphocytes and 1047 macrophages quantification in spleens of untreated (n=14), silibinin (n=8) and baricitinib 1048 (n=16) vFLIP mice by H&E staining. Scale bar, 200 µm. (C) Pathological score of lungs of 1049 untreated (n=14), silibinin (n=8) and baricitinib (n=16) vFLIP mice by H&E staining. Scale 1050 bar, 200 µm. (D) tSNE representation of scRNA-seq from untreated (4,662) mice and 1051 treated with silibinin (3,414) and baricitinib (4,177) colored according to cell type. Stacked 1052 bar plots representing cell type proportions across conditions. (E) Bar plot representing 1053 the up- and down-regulated (adjusted p-value < 0.05) hallmark gene sets obtained in the 1054 bulk-like analysis of treated compared to untreated vFLIP chimera cells obtained through 1055 GSEA analysis. (F) Violin plots showing the expression of genes involved in inflammatory 1056 response, JAK-STAT3 signaling pathway and interferon response in the lung of vFLIP 1057 chimera mice (*p < 0.05, **p < 0.01, ***p < 0.001). Data are reported as mean \pm 1058 S.E.M. *p \leq 0.05, **p \leq 0.01 and ***p \leq 0.001 by Student's *t*-test, Mann–Whitney test. 1059

1060



1063 Fig. 6. *In vivo* STAT3-silencing approach mitigates the evolution of 1064 immunopathological disorders in vFLIP mice.

(A) Pathological score of lungs of vFLIP mice (untreated, n=6; sh-scramble, n=5; sh-1065 STAT3, n=5) by H&E staining. Scale bar, 200 µm. (B) Flow cytometry analysis of CD45⁺ 1066 leukocytes isolated from lungs of vFLIP mice (untreated, n=6; sh-scramble, n=5; sh-1067 STAT3, n=5) or WT mice (n=5). (C) Lymphocytes and macrophages quantification in 1068 spleens of vFLIP mice (untreated, n=6; sh-scramble, n=5; sh-STAT3, n=5) by H&E 1069 staining. Scale bar, 400 µm. (D) Flow cytometry analysis in peripheral blood in vFLIP mice 1070 (untreated, n=6; sh-scramble, n=5; sh-STAT3, n=5) or WT mice (n=5). e Analysis of 1071 cytokines levels in serum of WT (n=5), sh-scramble (n=5) or sh-STAT3 (n=5) vFLIP mice. 1072 Data are reported as mean \pm S.E.M. *p \leq 0.05, **p \leq 0.01 and ***p \leq 0.001 by Mann-1073 Whitney test. 1074